Jun 2026 (Q2 FY26) — Aug 5, 2026
Mirum Pharmaceuticals Q2 FY26 — Strong Commercial Performance and Pipeline Progress Amidst Regulatory Delay for Volixibat in PSC
Read the full callMirum Pharmaceuticals (MIRM) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Mirum Pharmaceuticals earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 176 | +37.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -24.1 | −20.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -67.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$82.24 +2.62% · +$2.1
Performance +11.8% 1Y
1Y: $73.53 on 17 Oct 2025 → $82.24. High $128.57 (8 Jul 2026), low $64.1 (15 Dec 2025).
- Previous close
- $80.14
- 52-week range
- $64.1 – $128.57
- One year
- +12.61%
Overview
- Symbol
- MIRM
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Mirum Pharmaceuticals Q1 FY26 — Strong Commercial Growth and Pipeline Expansion
Read the full callDec 2025 (Q4 FY25) — Feb 25, 2026
Mirum Pharmaceuticals Q4 FY25 — Strong Sales Growth and Pivotal Pipeline Readouts Ahead
Read the full callEvery analysed call
Mirum Pharmaceuticals earnings calls (MIRM)
Financials
What the filings say
Net profit, year on year: −1047% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 90 | 99 | 112 | 128 | 133 | 149 | 160 | 176 |
| Operating profit | -13 | -24 | -15 | -5 | 3 | -5 | -789 | -43 |
| Operating margin | −14.0% | −24.4% | −13.6% | −3.9% | 2.0% | −3.1% | −493.8% | −24.1% |
| Interest | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Profit before tax | -14 | -24 | -14 | -5 | 3 | -5 | -790 | -66 |
| Tax rate | −2.5% | 2.4% | −7.5% | −7.4% | −9.9% | −15.4% | −0.1% | −2.6% |
| Net profit | -14 | -24 | -15 | -6 | 3 | -6 | -790 | -67 |
| EPS ($ per share) | -0.30 | — | -0.30 | -0.12 | 0.06 | — | -13.43 | -1.06 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -70 | -173 | -257 | -393 | -556 | -644 | -668 |
| Total liabilities | 16 | 69 | 174 | 211 | 398 | 445 | 528 |
| Fixed assets | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Investments | 105 | 90 | 125 | 124 | 0 | 58 | 87 |
| Total assets | 147 | 241 | 295 | 353 | 647 | 671 | 843 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -39 | -89 | -133 | -120 | -71 | 10 | 56 |
| Cash from investing | -128 | 38 | 49 | 8 | -107 | -90 | -24 |
| Cash from financing | 127 | 181 | 73 | 109 | 337 | 18 | 40 |
| Net cash flow | -40 | 130 | -11 | -3 | 158 | -63 | 75 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -1 | -1 |
| Free cash flow | -40 | -89 | -133 | -120 | -71 | 9 | 55 |
MIRM revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +37.9% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 78% ↓ 3 pt
- Non Us 22%
As MIRM cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
107 filings between Nov 18, 2025 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
$9.00M
1 purchase by 1 insider
Sales
$42.20M
59 sales by 7 insiders
64% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 45
- Option exercise — converted options into shares
Also filed: 1 gift, 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Peetz Christopher | — | $16.29M | Sep 1, 2026 |
| GREY MICHAEL G | — | $11.10M | Dec 19, 2025 |
| Heron Patrick J | $9.00M | — | Jan 23, 2026 |
| Howe Jolanda | — | $5.55M | Sep 2, 2026 |
| BJERKHOLT ERIC | — | $3.56M | Sep 14, 2026 |
| Radovich Peter | — | $2.32M | Mar 16, 2026 |
| Ramasastry Saira | — | $1.92M | Jun 1, 2026 |
| Quan Joanne | — | $1.46M | Mar 16, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Option exercise | 6,892 | $109.4K |
| Oct 6, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Option exercise | 5,305 | $101.8K |
| Sep 14, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale | 9,943 | $978.1K |
| Sep 11, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Option exercise | 18,333 | — |
| Sep 2, 2026 | Howe Jolanda SVP, GLOBAL CONTROLLER | Sale 10b5-1 plan | 658 | $65.8K |
| Sep 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 8,312 | $815.2K |
| Sep 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 21,688 | $2.15M |
| Sep 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 plan | 30,000 | $88.1K |
| Aug 18, 2026 | Howe Jolanda SVP, GLOBAL CONTROLLER | Option exercise | 40,000 | $250.8K |
| Aug 18, 2026 | Howe Jolanda SVP, GLOBAL CONTROLLER | Sale | 40,000 | $4.00M |
| Aug 11, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 6,001 | $599.5K |
| Aug 10, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 2,300 | $230.3K |
| Aug 10, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 6,017 | $597.2K |
| Aug 10, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 11,683 | $1.15M |
| Aug 10, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 plan | 20,000 | $58.7K |
| Aug 3, 2026 | Howe Jolanda SVP, GLOBAL CONTROLLER | Sale 10b5-1 plan | 1,840 | $193.7K |
| Jul 6, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 4,181 | $511.5K |
| Jul 6, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 12,134 | $1.48M |
| Jul 6, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 plan | 20,000 | $58.7K |
| Jul 6, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 300 | $37.5K |
| Jul 6, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 528 | $65.4K |
| Jul 6, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 1,975 | $244.4K |
| Jul 6, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 1,048 | $128.3K |
| Jul 6, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 1,710 | $213.4K |
| Jul 6, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 3,124 | $380.1K |
| Jul 1, 2026 | Howe Jolanda SVP, GLOBAL CONTROLLER | Sale 10b5-1 plan | 2,721 | $326.5K |
| Jun 17, 2026 | Howe Jolanda SVP, GLOBAL CONTROLLER | Sale 10b5-1 plan | 2,594 | $264.5K |
| Jun 9, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 2,393 | $63.4K |
| Jun 8, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 2,258 | $209.6K |
| Jun 8, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 1,567 | $149.1K |
| Jun 8, 2026 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 1,175 | $110.4K |
| Jun 5, 2026 | Radovich Peter PRESIDENT AND COO | Option exercise | 16,988 | $326.0K |
| Jun 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 16,595 | $1.58M |
| Jun 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 2,602 | $246.3K |
| Jun 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 plan | 30,000 | $88.1K |
| Jun 1, 2026 | Ramasastry Saira Director | Sale | 3,977 | $397.7K |
| Jun 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 6,926 | $665.9K |
| Jun 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 1,973 | $192.5K |
| Jun 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 883 | $88.0K |
| Jun 1, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 1,021 | $100.3K |
| May 29, 2026 | Fischer Laurent Director | Option exercise | 3,977 | — |
| May 29, 2026 | Ramasastry Saira Director | Option exercise | 3,977 | — |
| May 29, 2026 | Cardon Lon Director | Option exercise | 3,977 | — |
| May 29, 2026 | Walbert Timothy P Director | Option exercise | 3,977 | — |
| May 15, 2026 | Ramasastry Saira Director | Option exercise 10b5-1 plan | 2,000 | $47.0K |
| May 15, 2026 | Ramasastry Saira Director | Sale 10b5-1 plan | 2,000 | $218.9K |
| Apr 15, 2026 | Ramasastry Saira Director | Sale 10b5-1 plan | 2,000 | $193.8K |
| Apr 15, 2026 | Ramasastry Saira Director | Option exercise 10b5-1 plan | 2,000 | $47.0K |
| Mar 16, 2026 | Radovich Peter PRESIDENT AND COO | Sale | 16,515 | $1.52M |
| Mar 16, 2026 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Sale | 40,985 | $3.77M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Mirum Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Mirum Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading